| |
Without TXA |
With TXA |
| Number (n) |
25 |
81 |
| Gender (proportion of female %) |
60 |
57 |
| Age (years) |
73 ± 10 |
67 ± 12 |
| Comorbidities |
|
|
| Body mass index (kg/m2) |
26 ± 4 |
27 ± 5 |
| Median ASA score (Q1;Q3) |
3 (3;3) |
2 (2;2) |
| Cardio-vascular history (%) |
80 |
14 |
| Antiplatelet agents at D-30 (%) |
44 |
20 |
| Anticoagulant agents D-30 (%) |
28 |
2 |
| Hb D-1 (g/dL) |
13.3 ± 1.1 |
13.4 ± 1.1 |
| Type of surgery |
|
|
| THR (%) |
60 |
50 |
| TKR (%) |
32 |
29 |
| RTHR (%) |
8 |
21 |
| Perioperative period |
|
|
| Tranexamic acid |
|
|
| Intraoperative dose (mg/kg) |
0 |
17 ± 15 |
| Dose per 24h (mg/kg/24h) |
0 |
75 ± 25 |
| Fluids (intraoperative and RR, in mL) |
2140 ± 700 |
2080 ± 764 |
| Postoperative intravenous iron (%) |
80 |
87 |
| Transfusion |
|
|
| Allogeneic transfusion (between D0 et D+5, in %) |
40 |
11 |
| Number of transfused patients (n) |
10 |
9 |
| THR (%) |
40 |
5 |
| TKR (%) |
25 |
5 |
| RTHR (%) |
100 |
38 |
| Median number of RBC unit (Q1,Q3) |
2 (2;3) |
2 (2;2) |
| Mean Hb transfusional threshold (g/dL) |
8.4 ± 1,3 |
9.1 ± 0,6 |
TXA: Tranexamic Acid; ASA: American Society of Anesthesiology; Hb: Hemoglobin;
THR: Total Hip Replacement; TKR: Total Knee Replacement; RTHR: Revision
Total Hip Replacement; RBC: Red Blood Cell